BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla SDK Now Available for Game Developers Globally3.3.2026 15:48:00 CET | Press release
Backed by 20 years of Game Commerce Innovation, Xsolla SDK is a Platform Agnostic Software Development Kit that Game Developers Can Now Use to Seamlessly Expand Monetization Across Mobile, PC, and Web Xsolla, a global video game commerce company that has helped developers launch, grow, and monetize their games, today announced the availability of Xsolla SDK, a unified, cross-platform software development kit that consolidates the company's PC, mobile, and web monetization tools into a single download. Launching at GDC Festival of Games 2026, the Xsolla SDK introduces built-in Payments, Login, Catalog, and Offerwall integration for developers, enabling them to configure their pricing and inventory once and deploy across every supported platform with no reconfiguration required. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303075966/en/ Graphic: Xsolla Xsolla is building all the things to help developers monetize cross-pl
ZAPI GROUP to Showcase New Electrification Solutions at ConExpo/AGG 20263.3.2026 15:03:00 CET | Press release
Electrification leader demonstrates expanded low & high voltage capabilities at North America’s largest construction show ZAPI GROUP, a global leader in electrification, will demonstrate new solution capabilities within industrial vehicle electrification at ConExpo/AGG, taking place (March 3-7) in Las Vegas. As electrified construction equipment evolves to include larger, more demanding applications, the group has developed new higher-powered on-board DC/DC converters, inverters, electrical motors, and battery chargers to support those performance requirements, while combining additional utility functions within a compact form-factor. Featured solutions include: For motive power applications, a third-generation high-voltage inverter (ACH3) with customizable control software for enhanced performance, and a permanent magnet, electrical motor solution (IMI), with an integrated, liquid-cooled power-electronic inverter. On the battery-charging front, there will be new high-voltage, high-pow
Carta Launches CRM with Acquisition of ListAlpha3.3.2026 15:01:00 CET | Press release
Acquisition expands Carta’s AI-first ERP for private capital, creating an institutional-grade platform for deal teams and fundraising professionals to increase capital velocity Carta, the world’s first fully interconnected system for private capital, today announced it has acquired ListAlpha, the AI-powered CRM and relationship intelligence platform. The acquisition marks the launch of Carta CRM, a major expansion of the Carta ERP that further unifies front-to-back office workflows for the private markets. Private equity and venture capital firms have long operated in a fragmented way, keeping relationship context in siloed CRMs while fund performance data remains trapped in back-office ledgers. This information silo quietly erodes clarity for deal teams and GPs, slowing down teams and decreasing capital velocity. By integrating ListAlpha’s specialized CRM directly into the Carta ecosystem, firms can unify front-office intelligence with back-office execution on a single platform. Effec
Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation3.3.2026 15:00:00 CET | Press release
Rimini Support™ for SAP helps French brake parts manufacturer avoid unwanted move to RISE with SAP, strengthen security and compliance readiness and reinvest freed capital into R&D and modernization initiatives Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Flexitech, a French manufacturer of brake and cooling hose solutions for the global automotive industry, has selected Rimini Support™ for SAP to strengthen security, accelerate compliance readiness and free budget for innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303263951/en/ Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation Rimini Support™ Enables Stability, Compliance and Strategic Reinvestment Flexitech relies on a stable SAP ECC 6 environment to support its w
Connect44 Selects Sitetracker to Power Efficient, Scalable Fiber and Wireless Rollouts3.3.2026 15:00:00 CET | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that Connect44 has selected Sitetracker to support the delivery of its fiber and wireless network projects across Germany, UK and the PMO organisation. By consolidating project execution, field data capture, and reporting on a single platform, Connect44 aims to accelerate delivery speed, reduce operational risk, and strengthen financial performance as it scales its rollout and managed services business. Connect44 provides managed services, professional services, and resource consulting for telecom operators, supporting networks from planning and design through deployment, operations, and optimization. As the company expands into large-scale rollout programs and acts as a general contractor coordinating multiple subcontractors, it identified the need for a centralized platform to replace spreadsheets and operator-specific tools. Sitetracker will serve as Connect44’s system
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom